Paediatric retinal dysfunction linked to high vigabatrin doses

Article

Paediatric retinal dysfunction may be linked to exposure to high daily doses of vigabatrin.

Paediatric retinal dysfunction may be linked to exposure to high daily doses of vigabatrin, reveals a study in the Journal of Paediatric Ophthalmology and Strabismus.

Dr Ulrika Kjellstrom and her team, Department of Ophthalmology, University of Lund, Sweden, investigated the full-field electroretinographies (ff-ERG) of 14 children who were administered vigabatrin.

Drug dosage parameters were compared in all participants, along with the ff-ERGs from healthy controls and were grouped according to age.

For the isolated rod response, combined rod-cone response and the 30 Hz flicker response there was reduced b-wave amplitudes. In 57% of the children who received vigabatrin there were significant changes in ff-ERG. The study showed no differences in cumulative doses or duration of medication.

The study suggests that careful follow-up should be performed for children who are administered vigabatrin, as high doses are linked to retinal dysfunction and photoreceptor damage.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.